Arterial thrombosis in children

References

• Streif W, Andrew M, Marzinotto V et al. Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood94(9), 3007–3014 (1999).
   PubMed Web of Science ®Google Scholar
• Scheer B, Perel A, Pfeiffer UJ. Clinical review: complications and risk factors of peripheral arterial catheters used for haemodynamic monitoring in anaesthesia and intensive care medicine. Crit. Care6(3), 199–204 (2002).
   PubMed Web of Science ®Google Scholar
• Downs JB, Chapman RL Jr, Hawkins IF Jr. Prolonged radial-artery catheterization. An evaluation of heparinized catheters and continuous irrigation. Arch. Surg.108(5), 671–673 (1974).
   PubMedGoogle Scholar
• American Association of Critical-Care Nurses. Evaluation of the effects of heparinized and nonheparinized flush solutions on the patency of arterial pressure monitoring lines: the AACN Thunder Project. Am. J. Crit. Care2(1), 3–15 (1993).
   PubMedGoogle Scholar
• Hoar PF, Wilson RM, Mangano DT, Avery GJ 2nd, Szarnicki RJ, Hill JD. Heparin bonding reduces thrombogenicity of pulmonary-artery catheters. N. Engl. J. Med.305(17), 993–995 (1981).
   PubMed Web of Science ®Google Scholar
• Butt W, Shann F, McDonnell G, Hudson I. Effect of heparin concentration and infusion rate on the patency of arterial catheters. Crit. Care Med.15(3), 230–232 (1987).
   PubMed Web of Science ®Google Scholar
• Clifton GD, Branson P, Kelly HJ et al. Comparison of normal saline and heparin solutions for maintenance of arterial catheter patency. Heart Lung20(2), 115–118 (1991).
   PubMed Web of Science ®Google Scholar
• Kulkarni M, Elsner C, Ouellet D, Zeldin R. Heparinized saline versus normal saline in maintaining patency of the radial artery catheter. Can. J. Surg.37(1), 37–42 (1994).
   PubMed Web of Science ®Google Scholar
• de Neef M, Heijboer H, van Woensel JB, de Haan RJ. The efficacy of heparinization in prolonging patency of arterial and central venous catheters in children: a randomized double-blind trial. Pediatr. Hematol. Oncol.19(8), 553–560 (2002).
   PubMed Web of Science ®Google Scholar
• Sellden H, Nilsson K, Larsson LE, Ekstrom-Jodal B. Radial arterial catheters in children and neonates: a prospective study. Crit. Care Med.15(12), 1106–1109 (1987).
   PubMed Web of Science ®Google Scholar
• Rais-Bahrami K, Karna P, Dolanski EA. Effect of fluids on life span of peripheral arterial lines. Am. J. Perinatol.7(2), 122–124 (1990).
   PubMed Web of Science ®Google Scholar
• Barrington KJ. Umbilical artery catheters in the newborn: effects of position of the catheter tip. Cochrane Database Syst. Rev. (2), CD000505 (2000).
   Google Scholar
• Barrington KJ. Umbilical artery catheters in the newborn: effects of catheter design (end vs side hole). Cochrane Database Syst. Rev. (2), CD000508 (2000).
   Google Scholar
• Barrington KJ. Umbilical artery catheters in the newborn: effects of catheter materials. Cochrane Database Syst. Rev. (2), CD000949 (2000).
   Google Scholar
• Barrington KJ. Umbilical artery catheters in the newborn: effects of heparin. Cochrane Database Syst. Rev. (2), CD000507 (2000).
   Google Scholar
• Wesstrom G, Finnstrom O, Stenport G. Umbilical artery catheterization in newborns. I. Thrombosis in relation to catheter type and position. Acta Paediatr. Scand.68(4), 575–581 (1979).
   PubMed Web of Science ®Google Scholar
• Jackson JC, Truog WE, Watchko JF, Mack LA, Cyr DR, van Belle G. Efficacy of thromboresistant umbilical artery catheters in reducing aortic thrombosis and related complications. J. Pediatr.110(1), 102–105 (1987).
   PubMed Web of Science ®Google Scholar
• Boros SJ, Thompson TR, Reynolds JW, Jarvis CW, Williams HJ. Reduced thrombus formation with silicone elastomere (silastic) umbilical artery catheters. Pediatrics56(6), 981–986 (1975).
   PubMed Web of Science ®Google Scholar
• Bosque E, Weaver L. Continuous versus intermittent heparin infusion of umbilical artery catheters in the newborn infant. J. Pediatr.108(1), 141–143 (1986).
   PubMed Web of Science ®Google Scholar
• Horgan MJ, Bartoletti A, Polansky S, Peters JC, Manning TJ, Lamont BM. Effect of heparin infusates in umbilical arterial catheters on frequency of thrombotic complications. J. Pediatr.111(5), 774–778 (1987).
   PubMed Web of Science ®Google Scholar
• Ankola PA, Atakent YS. Effect of adding heparin in very low concentration to the infusate to prolong the patency of umbilical artery catheters. Am. J. Perinatol.10(3), 229–232 (1993).
   PubMed Web of Science ®Google Scholar
• David RJ, Merten DF, Anderson JC, Gross S. Prevention of umbilical artery catheter clots with heparinized infusates. Dev. Pharmacol. Ther.2(2), 117–126 (1981).
   PubMedGoogle Scholar
• Monagle P, Chan A, Massicotte P, Chalmers E, Michelson AD. Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest126(3 Suppl.), 645S–687S (2004).
   Web of Science ®Google Scholar
• Lesko SM, Mitchell AA, Epstein MF, Louik C, Giacoia GP, Shapiro S. Heparin use as a risk factor for intraventricular hemorrhage in low-birth-weight infants. N. Engl. J. Med.314(18), 1156–1160 (1986).
   PubMed Web of Science ®Google Scholar
• Malloy MH, Cutter GR. The association of heparin exposure with intraventricular hemorrhage among very low birth weight infants. J. Perinatol.15(3), 185–191 (1995).
   PubMedGoogle Scholar
• Stanger P, Heymann MA, Tarnoff H, Hoffman JI, Rudolph AM. Complications of cardiac catheterization of neonates, infants, and children. A three-year study. Circulation50(3), 595–608 (1974).
   PubMed Web of Science ®Google Scholar
• Kocis KC, Snider AR, Vermilion RP, Beekman RH. Two-dimensional and Doppler ultrasound evaluation of femoral arteries in infants after cardiac catheterization. Am. J. Cardiol.75(8), 642–645 (1995).
   PubMed Web of Science ®Google Scholar
• Vitiello R, McCrindle BW, Nykanen D, Freedom RM, Benson LN. Complications associated with pediatric cardiac catheterization. J. Am. Coll. Cardiol.32(5), 1433–1440 (1998).
   PubMed Web of Science ®Google Scholar
• Saxena A, Gupta R, Kumar RK, Kothari SS, Wasir HS. Predictors of arterial thrombosis after diagnostic cardiac catheterization in infants and children randomized to two heparin dosages. Cathet. Cardiovasc. Diagn.41(4), 400–403 (1997).
   PubMedGoogle Scholar
• Bulbul ZR, Galal MO, Mahmoud E et al. Arterial complications following cardiac catheterization in children less than 10 kg. Asian Cardiovasc. Thorac. Ann.10(2), 129–132 (2002).
   PubMedGoogle Scholar
• Freed MD, Keane JF, Rosenthal A. The use of heparinization to prevent arterial thrombosis after percutaneous cardiac catheterization in children. Circulation50(3), 565–569 (1974).
   PubMed Web of Science ®Google Scholar
• Schmidt B, Andrew M. Neonatal thrombotic disease: prevention, diagnosis, and treatment. J. Pediatr.113(2), 407–410 (1988).
   PubMedGoogle Scholar
• Ino T, Benson LN, Freeman RM, Barker GA, Zipursky A, Rowe RD. Thrombolytic therapy for femoral artery thrombosis after pediatric cardiac catheterization. Am. Heart J.115, 633–639 (1988).
   PubMed Web of Science ®Google Scholar
• Bontadelli J, Moeller A, Schmugge M et al. Enoxaparin therapy for arterial thrombosis in infants with congenital heart disease. Intensive Care Med.33(11), 1978–1984 (2007).
   PubMed Web of Science ®Google Scholar
• Marsh JL, King W, Barrett C, Fonkalsrud EW. Serious complications after umbilical artery catheterization for neonatal monitoring. Arch. Surg.110(10), 1203–1208 (1975).
   PubMedGoogle Scholar
• Wigger HJ, Bransilver BR, Blanc WA. Thromboses due to catheterization in infants and children. J. Pediatr.76(1), 1–11 (1970).
   PubMed Web of Science ®Google Scholar
• Letts M, Blastorah B, al-Azzam S. Neonatal gangrene of the extremities. J. Pediatr. Orthop.17(3), 397–401 (1997).
   PubMed Web of Science ®Google Scholar
• Munoz ME, Roche C, Escriba R, Martinez-Bermejo A, Pascual-Castroviejo I. Flaccid paraplegia as complication of umbilical artery catheterization. Pediatr. Neurol.9(5), 401–403 (1993).
   PubMed Web of Science ®Google Scholar
• Mayer T, Matlak ME, Thompson JA. Necrosis of the forearm following radial artery catheterization in a patient with Reye’s syndrome. Pediatrics65(1), 141–143 (1980).
   PubMed Web of Science ®Google Scholar
• van Ommen CH, Ottenkamp J, Lam J et al. The risk of postthrombotic syndrome in children with congenital heart disease. J. Pediatr.141(4), 582–586 (2002).
   PubMed Web of Science ®Google Scholar
• Kerr GS, Hallahan CW, Giordano J et al. Takayasu arteritis. Ann. Intern. Med.120(11), 919–929 (1994).
   PubMed Web of Science ®Google Scholar
• Martini A. Behcet’s disease and Takayasu’s disease in children. Curr. Opin. Rheumatol.7(5), 449–454 (1995).
   PubMedGoogle Scholar
• Brogan PA, Dillon MJ. Vasculitis from the pediatric perspective. Curr. Rheumatol. Rep.2(5), 411–416 (2000).
   PubMedGoogle Scholar
• Park JH, Chung JW, Lee KW, Park YB, Han MC. CT angiography of Takayasu arteritis: comparison with conventional angiography. J. Vasc. Interv. Radiol.8(3), 393–400 (1997).
   PubMed Web of Science ®Google Scholar
• Tanigawa K, Eguchi K, Kitamura Y et al. Magnetic resonance imaging detection of aortic and pulmonary artery wall thickening in the acute stage of Takayasu arteritis. Improvement of clinical and radiologic findings after steroid therapy. Arthritis Rheum.35(4), 476–480 (1992).
   PubMedGoogle Scholar
• Yamada I, Numano F, Suzuki S. Takayasu arteritis: evaluation with MR imaging. Radiology188(1), 89–94 (1993).
   PubMed Web of Science ®Google Scholar
• Shulman ST, De Inocencio J, Hirsch R. Kawasaki disease. Pediatr. Clin. North Am.42(5), 1205–1222 (1995).
   PubMed Web of Science ®Google Scholar
• Diagnostic guidelines for Kawasaki disease. American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease. Am. J. Dis. Child.144(11), 1218–1219 (1990).
   PubMedGoogle Scholar
• Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics63(2), 175–179 (1979).
   PubMed Web of Science ®Google Scholar
• Brogan PA, Bose A, Burgner D et al. Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research. Arch. Dis. Child.86(4), 286–290 (2002).
   PubMed Web of Science ®Google Scholar
• Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J. Pediatr.131(6), 888–893 (1997).
   PubMed Web of Science ®Google Scholar
• Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics96(6), 1057–1061 (1995).
   PubMed Web of Science ®Google Scholar
• Newburger JW, Sleeper LA, McCrindle BW et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N. Engl. J. Med.356(7), 663–675 (2007).
   PubMed Web of Science ®Google Scholar
• Inoue Y, Okada Y, Shinohara M et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J. Pediatr.149(3), 336–341 (2006).
   PubMed Web of Science ®Google Scholar
• Newburger JW. Kawasaki Disease. Curr. Treat. Options Cardiovasc. Med.2(3), 227–236 (2000).
   PubMedGoogle Scholar
• Weiss P, Soff GA, Halkin H, Seligsohn U. Decline of proteins C and S and factors II, VII, IX and X during the initiation of warfarin therapy. Thromb. Res.45(6), 783–790 (1987).
   PubMed Web of Science ®Google Scholar
• Williams RV, Wilke VM, Tani LY, Minich LL. Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease? Pediatrics109(1), E4 (2002).
   PubMed Web of Science ®Google Scholar
• Williams WG, Pollock JC, Geiss DM, Trusler GA, Fowler RS. Experience with aortic and mitral valve replacement in children. J. Thorac. Cardiovasc. Surg.81(3), 326–333 (1981).
   PubMed Web of Science ®Google Scholar
• Williams DB, Danielson GK, McGoon DC, Puga FJ, Mair DD, Edwards WD. Porcine heterograft valve replacement in children. J. Thorac. Cardiovasc. Surg.84(3), 446–450 (1982).
   PubMed Web of Science ®Google Scholar
• Solymar L, Rao PS, Mardini MK, Fawzy ME, Guinn G. Prosthetic valves in children and adolescents. Am. Heart J.121(2 Pt 1), 557–568 (1991).
   PubMed Web of Science ®Google Scholar
• Stewart S, Cianciotta D, Alexson C, Manning J. The long-term risk of warfarin sodium therapy and the incidence of thromboembolism in children after prosthetic cardiac valve replacement. J. Thorac. Cardiovasc. Surg.93(4), 551–554 (1987).
   PubMed Web of Science ®Google Scholar
• Bradley LM, Midgley FM, Watson DC, Getson PR, Scott LP, 3rd. Anticoagulation therapy in children with mechanical prosthetic cardiac valves. Am. J. Cardiol.56(8), 533–535 (1985).
   PubMed Web of Science ®Google Scholar
• Woods A, Vargas J, Berri G, Kreutzer G, Meschengieser S, Lazzari MA. Antithrombotic therapy in children and adolescents. Thromb. Res.42(3), 289–301 (1986).
   PubMed Web of Science ®Google Scholar
• Tamisier D, Vouhe PR, Vernant F, Leca F, Massot C, Neveux JY. Modified Blalock-Taussig shunts: results in infants less than 3 months of age. Ann. Thorac. Surg.49(5), 797–801 (1990).
   PubMed Web of Science ®Google Scholar
• Ries M, Singer H, Hofbeck M. Thrombolysis of a modified Blalock-Taussig shunt with recombinant tissue plasminogen activator in a newborn infant with pulmonary atresia and ventricular septal defect. Br. Heart J.72(2), 201–202 (1994).
   PubMedGoogle Scholar
• Tsai KT, Chang CH, Lin PJ. Modified Blalock-Taussig shunt: statistical analysis of potential factors influencing shunt outcome. J. Cardiovasc. Surg. (Torino)37(2), 149–152 (1996).
   PubMed Web of Science ®Google Scholar
• Gladman G, McCrindle BW, Williams WG, Freedom RM, Benson LN. The modified Blalock-Taussig shunt: clinical impact and morbidity in Fallot’s tetralogy in the current era. J. Thorac. Cardiovasc. Surg.114(1), 25–30 (1997).
   PubMed Web of Science ®Google Scholar
• Rajani RM, Dalvi BV, Kulkarni HL, Kale PA. Acutely blocked Blalock-Taussig shunt following cardiac catheterization: successful recanalization with intravenous streptokinase. Am. Heart J.120(5), 1238–1239 (1990).
   PubMed Web of Science ®Google Scholar
• Fontan F, Baudet E. Surgical repair of tricuspid atresia. Thorax26(3), 240–248 (1971).
   PubMed Web of Science ®Google Scholar
• de Leval MR, Kilner P, Gewillig M, Bull C. Total cavopulmonary connection: a logical alternative to atriopulmonary connection for complex Fontan operations. Experimental studies and early clinical experience. J. Thorac. Cardiovasc. Surg.96(5), 682–695 (1988).
   PubMed Web of Science ®Google Scholar
• Gale AW, Danielson GK, McGoon DC, Mair DD. Modified Fontan operation for univentricular heart and complicated congenital lesions. J. Thorac. Cardiovasc. Surg.78(6), 831–838 (1979).
   PubMed Web of Science ®Google Scholar
• Jahangiri M, Ross DB, Redington AN, Lincoln C, Shinebourne EA. Thromboembolism after the Fontan procedure and its modifications. Ann. Thorac. Surg.58(5), 1409–1413; discussion 1413–1404 (1994).
   PubMed Web of Science ®Google Scholar
• Monagle P, Cochrane A, McCrindle B, Benson L, Williams W, Andrew M. Thromboembolic complications after fontan procedures – the role of prophylactic anticoagulation. J. Thorac. Cardiovasc. Surg.115(3), 493–498 (1998).
   PubMed Web of Science ®Google Scholar
• Monagle P, Karl TR. Thromboembolic problems after the Fontan operation. Semin. Thorac. Cardiovasc. Surg. Pediatr. Card. Surg. Annu.536–47 (2002).
   PubMedGoogle Scholar
• van Nieuwenhuizen RC, Peters M, Lubbers LJ, Trip MD, Tijssen JG, Mulder BJ. Abnormalities in liver function and coagulation profile following the Fontan procedure. Heart82(1), 40–46 (1999).
   PubMed Web of Science ®Google Scholar
• Jain A, Costa G, Marsh W et al. Thrombotic and nonthrombotic hepatic artery complications in adults and children following primary liver transplantation with long-term follow-up in 1000 consecutive patients. Transpl. Int.19(1), 27–37 (2006).
   PubMed Web of Science ®Google Scholar
• Rela M, Muiesan P, Bhatnagar V et al. Hepatic artery thrombosis after liver transplantation in children under 5 years of age. Transplantation61(9), 1355–1357 (1996).
   PubMed Web of Science ®Google Scholar
• Dunn SP, Billmire DF, Falkenstein K et al. Rejection after pediatric liver transplantation is not the limiting factor to survival. J. Pediatr. Surg.29(8), 1141–1143; discussion 1143–1144 (1994).
   PubMed Web of Science ®Google Scholar
• Drazan K, Shaked A, Olthoff KM et al. Etiology and management of symptomatic adult hepatic artery thrombosis after orthotopic liver transplantation (OLT). Am. Surg.62(3), 237–240 (1996).
   PubMed Web of Science ®Google Scholar
• Garcia-Gallont R, Bar-Nathan N, Shaharabani E et al. Hepatic artery thrombosis in pediatric liver transplantation: graft salvage after thrombectomy. Pediatr. Transplant.3(1), 74–78 (1999).
   PubMedGoogle Scholar
• Zhou J, Fan J, Wang JH et al. Continuous transcatheter arterial thrombolysis for early hepatic artery thrombosis after liver transplantation. Transplant Proc.37(10), 4426–4429 (2005).
   PubMed Web of Science ®Google Scholar
• Harmon WE, Stablein D, Alexander SR, Tejani A. Graft thrombosis in pediatric renal transplant recipients. A report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation51(2), 406–412 (1991).
   PubMed Web of Science ®Google Scholar
• Singh A, Stablein D, Tejani A. Risk factors for vascular thrombosis in pediatric renal transplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation63(9), 1263–1267 (1997).
   PubMed Web of Science ®Google Scholar
• Kranz B, Vester U, Nadalin S, Paul A, Broelsch CE, Hoyer PF. Outcome after kidney transplantation in children with thrombotic risk factors. Pediatr. Transplant.10(7), 788–793 (2006).
   PubMed Web of Science ®Google Scholar
• Heidenreich S, Dercken C, August C, Koch HG, Nowak-Gottl U. High rate of acute rejections in renal allograft recipients with thrombophilic risk factors. J. Am. Soc. Nephrol.9(7), 1309–1313 (1998).
   PubMed Web of Science ®Google Scholar
• Smith JM, Stablein D, Singh A, Harmon W, McDonald RA. Decreased risk of renal allograft thrombosis associated with interleukin-2 receptor antagonists: a report of the NAPRTCS. Am. J. Transplant.585–588 (2006).
   PubMed Web of Science ®Google Scholar
• Ostuni PA, Lazzarin P, Pengo V, Ruffatti A, Schiavon F, Gambari P. Renal artery thrombosis and hypertension in a 13 year old girl with antiphospholipid syndrome. Ann. Rheum. Dis.49(3), 184–187 (1990).
   PubMed Web of Science ®Google Scholar
• Dinchman KH, Spirnak JP. Traumatic renal artery thrombosis: evaluation and treatment. Semin. Urol.13(1), 90–93 (1995).
   PubMedGoogle Scholar
• Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br. J. Haematol.121(4), 535–555 (2003).
   PubMed Web of Science ®Google Scholar
• Spadone D, Clark F, James E, Laster J, Hoch J, Silver D. Heparin-induced thrombocytopenia in the newborn. J. Vasc. Surg.15(2), 306–311; discussion 311–302 (1992).
   PubMed Web of Science ®Google Scholar
• Klenner AF, Lubenow N, Raschke R, Greinacher A. Heparin-induced thrombocytopenia in children: 12 new cases and review of the literature. Thromb. Haemost.91(4), 719–724 (2004).
   PubMed Web of Science ®Google Scholar
• Newall F, Barnes C, Ignjatovic V, Monagle P. Heparin-induced thrombocytopenia in children. J. Paediatr. Child Health39(4), 289–292 (2003).
   PubMed Web of Science ®Google Scholar
• Klenner AF, Fusch C, Rakow A et al. Benefit and risk of heparin for maintaining peripheral venous catheters in neonates: a placebo-controlled trial. J. Pediatr.143(6), 741–745 (2003).
   PubMed Web of Science ®Google Scholar
• Risch L, Fischer JE, Herklotz R, Huber AR. Heparin-induced thrombocytopenia in paediatrics: clinical characteristics, therapy and outcomes. Intensive Care Med.30(8), 1615–1624 (2004).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N. Engl. J. Med.344(17), 1286–1292 (2001).
   PubMed Web of Science ®Google Scholar
• Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: a critical review. Arch. Intern. Med.164(4), 361–369 (2004).
   PubMedGoogle Scholar
• Vossen CY, Rosendaal FR. Risk of arterial thrombosis in carriers of familial thrombophilia. J. Thromb. Haemost.4(4), 916–918 (2006).
   PubMed Web of Science ®Google Scholar
• Rosendaal FR, Siscovick DS, Schwartz SM et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood89(8), 2817–2821 (1997).
   PubMed Web of Science ®Google Scholar
• No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation107(8), 1117–1122 (2003).
   PubMed Web of Science ®Google Scholar
• Proesmans W, van de Wijdeven P, Van Geet C. Thrombophilia in neonatal renal venous and arterial thrombosis. Pediatr. Nephrol.20(2), 241–242 (2005).
   PubMed Web of Science ®Google Scholar
• Albisetti M, Moeller A, Waldvogel K et al. Congenital prothrombotic disorders in children with peripheral venous and arterial thromboses. Acta Haematol.117(3), 149–155 (2007).
   PubMed Web of Science ®Google Scholar
• Haitas B, Baker SG, Meyer TE, Joffe BI, Seftel HC. Natural history and cardiac manifestations of homozygous familial hypercholesterolaemia. QJ Med.76(279), 731–740 (1990).
   PubMedGoogle Scholar
• Clarke R, Daly L, Robinson K et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N. Engl. J. Med.324(17), 1149–1155 (1991).
   PubMed Web of Science ®Google Scholar
• Mudd SH, Skovby F, Levy HL et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am. J. Hum. Genet.37(1), 1–31 (1985).
   PubMed Web of Science ®Google Scholar
• Wada Y, Narisawa K, Arakawa T. Infantile type of homocystinuria with 5,10-methylenetetrahydrofolate reductase deficiency. Monogr. Hum. Genet.9140–146 (1978).
   PubMedGoogle Scholar
• Taylor BV, Oudit GY, Evans M. Homocysteine, vitamins, and coronary artery disease. Comprehensive review of the literature. Can. Fam. Physician462236–2245 (2000).
   PubMed Web of Science ®Google Scholar
• Parmar N, Albisetti M, Berry LR, Chan AK. The fibrinolytic system in newborns and children. Clin. Lab.52(3–4), 115–124 (2006).
   PubMed Web of Science ®Google Scholar
• Ries M, Zenker M, Klinge J, Keuper H, Harms D. Age-related differences in a clot lysis assay after adding different plasminogen activators in a plasma milieu in vitro. J. Pediatr. Hematol. Oncol.17(3), 260–264 (1995).
   PubMed Web of Science ®Google Scholar
• Richardson MW, Allen GA, Monahan PE. Thrombosis in children: current perspective and distinct challenges. Thromb. Haemost.88(6), 900–911 (2002).
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Grabowski EF, Hellgreen M et al. Recommendations for tPA thrombolysis in children. On behalf of the Scientific Subcommittee on Perinatal and Pediatric Thrombosis of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb. Haemost.88(1), 157–158 (2002).
   PubMed Web of Science ®Google Scholar
• Wang M, Hays T, Balasa V et al. Low-dose tissue plasminogen activator thrombolysis in children. J. Pediatr. Hematol. Oncol.25(5), 379–386 (2003).
   PubMed Web of Science ®Google Scholar
• Hartmann J, Hussein A, Trowitzsch E, Becker J, Hennecke KH. Treatment of neonatal thrombus formation with recombinant tissue plasminogen activator: six years experience and review of the literature. Arch. Dis. Child Fetal Neonatal Ed.85(1), F18–F22 (2001).
   PubMed Web of Science ®Google Scholar
• Zenz W, Muntean W, Beitzke A, Zobel G, Riccabona M, Gamillscheg A. Tissue plasminogen activator (alteplase) treatment for femoral artery thrombosis after cardiac catheterisation in infants and children. Br. Heart J.70(4), 382–385 (1993).
   PubMedGoogle Scholar
• Manco-Johnson MJ, Nuss R, Hays T, Krupski W, Drose J, Manco-Johnson ML. Combined thrombolytic and anticoagulant therapy for venous thrombosis in children. J. Pediatr.136(4), 446–453 (2000).
   PubMed Web of Science ®Google Scholar
• Gupta AA, Leaker M, Andrew M et al. Safety and outcomes of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children. J. Pediatr.139(5), 682–688 (2001).
   PubMed Web of Science ®Google Scholar